IMAB – I-Mab ADR
I-MABIMAB
$2.45Name : I-MAB
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $200,067,744.00
EPSttm : -0.55
I-MAB
$2.45
6.99%$0.16Float Short %
0.36
Margin Of Safety %
Put/Call OI Ratio
0.07
EPS Next Q Diff
EPS Last/This Y
0.1
EPS This/Next Y
-0.08
Price
2.44
Target Price
5.4
Analyst Recom
1
Performance Q
185.91
Relative Volume
4.86
Beta
1.12
Ticker: IMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-09 | IMAB | 0.8527 | N/A | N/A | 0 |
| 2025-05-12 | IMAB | 0.9449 | N/A | N/A | 0 |
| 2025-05-13 | IMAB | 0.912 | N/A | N/A | 0 |
| 2025-05-14 | IMAB | 0.8914 | N/A | N/A | 0 |
| 2025-05-15 | IMAB | 0.8875 | N/A | N/A | 0 |
| 2025-05-16 | IMAB | 0.8959 | N/A | N/A | 0 |
| 2025-05-19 | IMAB | 0.9109 | 0.00 | 0.00 | 323 |
| 2025-05-20 | IMAB | 0.9134 | 0.00 | 0.00 | 226 |
| 2025-05-21 | IMAB | 0.94 | 0.00 | 0.00 | 226 |
| 2025-05-22 | IMAB | 1.06 | 0.00 | 0.00 | 266 |
| 2025-05-23 | IMAB | 0.9899 | 0.00 | 0.00 | 266 |
| 2025-05-27 | IMAB | 1.04 | 0.00 | 0.00 | 298 |
| 2025-05-28 | IMAB | 1.18 | 0.00 | 0.00 | 308 |
| 2025-05-29 | IMAB | 1.28 | 0.00 | 0.00 | 355 |
| 2025-05-30 | IMAB | 1.31 | 0.00 | 0.00 | 385 |
| 2025-06-02 | IMAB | 1.28 | 0.00 | 0.00 | 385 |
| 2025-06-03 | IMAB | 1.88 | 0.00 | 0.13 | 411 |
| 2025-06-04 | IMAB | 1.79 | 0.07 | 0.13 | 693 |
| 2025-06-05 | IMAB | 2.22 | 0.08 | 0.02 | 643 |
| 2025-06-06 | IMAB | 2.45 | 0.07 | 0.01 | 807 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-09 | IMAB | 0.88 | - | - | -0.28 |
| 2025-05-12 | IMAB | 0.94 | - | - | -0.28 |
| 2025-05-13 | IMAB | 0.92 | - | - | -0.28 |
| 2025-05-14 | IMAB | 0.89 | - | - | -0.28 |
| 2025-05-15 | IMAB | 0.89 | - | - | -0.28 |
| 2025-05-16 | IMAB | 0.90 | - | - | -0.28 |
| 2025-05-19 | IMAB | 0.91 | - | - | -0.17 |
| 2025-05-20 | IMAB | 0.91 | - | - | -0.17 |
| 2025-05-21 | IMAB | 0.94 | - | - | -0.17 |
| 2025-05-22 | IMAB | 1.05 | - | - | -0.17 |
| 2025-05-23 | IMAB | 1.05 | - | - | -0.17 |
| 2025-05-27 | IMAB | 1.04 | - | - | -0.17 |
| 2025-05-28 | IMAB | 1.17 | - | - | -0.17 |
| 2025-05-29 | IMAB | 1.26 | - | - | -0.17 |
| 2025-05-30 | IMAB | 1.31 | - | - | -0.17 |
| 2025-06-02 | IMAB | 1.29 | - | - | -0.17 |
| 2025-06-03 | IMAB | 1.87 | - | - | -0.17 |
| 2025-06-04 | IMAB | 1.79 | - | - | -0.17 |
| 2025-06-05 | IMAB | 2.29 | - | - | -0.17 |
| 2025-06-06 | IMAB | 2.44 | - | - | -0.17 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-09 | IMAB | 0.00 | -20.14 | 0.54 |
| 2025-05-12 | IMAB | 0.00 | -20.15 | 0.34 |
| 2025-05-13 | IMAB | 0.00 | -20.15 | 0.34 |
| 2025-05-14 | IMAB | 0.00 | -20.15 | 0.34 |
| 2025-05-15 | IMAB | 0.00 | -20.15 | 0.34 |
| 2025-05-16 | IMAB | 0.00 | -20.15 | 0.34 |
| 2025-05-19 | IMAB | 0.00 | -19.28 | 0.34 |
| 2025-05-20 | IMAB | 0.00 | -19.28 | 0.34 |
| 2025-05-21 | IMAB | 0.00 | -19.28 | 0.34 |
| 2025-05-22 | IMAB | 0.00 | -19.28 | 0.34 |
| 2025-05-23 | IMAB | 0.00 | -19.28 | 0.34 |
| 2025-05-27 | IMAB | 0.00 | -44.03 | 0.34 |
| 2025-05-28 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-05-29 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-05-30 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-02 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-03 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-04 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-05 | IMAB | 0.00 | -44.03 | 0.36 |
| 2025-06-06 | IMAB | 0.00 | -44.03 | 0.36 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.04
Avg. EPS Est. Next Quarter
-0.04
Insider Transactions
Institutional Transactions
-44.03
Beta
1.12
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
16
Growth Score
19
Sentiment Score
92
Actual DrawDown %
97.1
Max Drawdown 5-Year %
-99.3
Target Price
5.4
P/E
Forward P/E
PEG
P/S
P/B
1.01
P/Free Cash Flow
EPS
-0.71
Average EPS Est. Cur. Y
-0.17
EPS Next Y. (Est.)
-0.26
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
4.86
Return on Equity vs Sector %
-28.6
Return on Equity vs Industry %
-10.6
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.11
EBIT Estimation
I-MABSector: Healthcare
Industry: Biotechnology
Employees: 32
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
stock quote shares IMAB – I-Mab ADR Stock Price stock today
news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMAB – I-Mab ADR yahoo finance google finance
stock history IMAB – I-Mab ADR invest stock market
stock prices IMAB premarket after hours
ticker IMAB fair value insiders trading